Navigation Links
BioElectronics Corporation's Commercial Resumes on Bloomberg Television

ActiPatch(TM) Brand and Product Awareness On the Increase

FREDERICK, Md., July 15 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL), announced today that the company will resume airing an investment and product-related commercial on financial network Bloomberg Television. CEO of BioElectronics, Andrew Whelan says, "We previously ran this commercial in April with significant success relating both to our equity and product awareness. We are excited to see these commercials airing again today and reaching millions of people."

ActiPatch(TM), the product marketed by BioElectronics Corp. is changing the face of medicine and the way we heal. Recently chosen as "One of 9 Medical Breakthroughs That May Change Your Life," by, ActiPatch(TM) is fast becoming the treatment of choice for everything from soft tissue injuries to surgical recovery.

ActiPatch(TM) is a drug-free wafer thin patch with an embedded battery- operated microchip that delivers weeks of continuous pulsed RF therapy for less than a dollar a day. The unique ActiPatch(TM) delivery system, using patented technology, provides a cost-effective, home use method that reduces soft tissue pain and swelling, and accelerates healing.

ActiPatch(TM) is very thin, easily applied and comfortable to wear on an injured area. The patch effectively minimizes pain and swelling. Physicians are so impressed with the power of the patch that they are providing it to their patients for uses beyond plastic surgery recovery.

Distribution has expanded into Canada, Italy, Switzerland, Denmark, Scandinavian countries, Singapore, Malaysia and India.

For more information visit or call 866-757-2284.

About BioElectronics Corporation

BioElectronics Corporation is the maker of the ActiPatch(TM). ActiPatch(TM) is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for about a dollar a day. The unique ActiPatch(TM) delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling. ActiPatch(TM) is approved by Health Canada for the relief of pain in musculoskeletal complaints. The US government's food and drug administration (FDA) has cleared the use of the product for reducing edema (swelling) following blepharoplasty and the European Union has approved the product as a class two pulsed electromagnetic medical device as have numerous other international record for agencies.

Information on ActiPatch(TM) and BioElectronics Corporation is available at the following websites:
-- U.S. Consumer:

-- Podiatry:

-- Plastic Surgery: and

-- German orthopedic foot & ankle:

-- Italy and Switzerland:

-- Canada:

-- Netherlands:

-- Singapore & Malaysia:

-- BioElectronics Corp:

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.

Media Relations Contact:

Patricia Baker, The Big Picture Agency LLC

Voice: 413-623-0950 ext. 221, email:

Investor Relations Contact:

Joe Noel, Emerging Growth Research LLP

Voice: 925-922-2560, email:

SOURCE BioElectronics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. BioElectronics Corporation Receives 2007 Economic Development Innovator of the Year Award
2. BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales
3. BioElectronics Corporation (BIEL) SqueezeTrigger Price is $0.11
4. BioElectronics Corporations New Commercial Airing Nationally Advertising Initiative Will Reach 15,000,000 Homes Nationwide
5. BioElectronics CEO Andrew Whelan: Positioning the Company for Growth During 2008 and Beyond
6. BioElectronics Corporation Announces New Website for Italian Market
7. Nationally Recognized Corporations and Retailers Rally Behind
8. BDSI secures US commercial partnership for BEMA Fentanyl with Meda AB
9. WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana
10. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
11. OmniGuide Begins European Commercialization
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: